Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis.
Hepatic transient elastography
Liver fibrosis
Lung fibrosis
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
14
03
2020
accepted:
12
05
2020
pubmed:
27
5
2020
medline:
14
9
2021
entrez:
27
5
2020
Statut:
ppublish
Résumé
Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of subclinical liver fibrosis in a cohort of patients with IPF. Patients referred to the Centre for Rare Lung Disease of the University Hospital of Modena (Italy) from March 2012 to February 2013 with established diagnosis of IPF and without a documented history of liver diseases were consecutively enrolled and underwent HTE. Based on hepatic stiffness status as assessed through METAVIR score patients were categorized as "with liver fibrosis" (corresponding to a METAVIR score of F1-F4) and "without liver fibrosis" (METAVIR F0). Potential predictors of liver fibrosis were investigated through logistic regression model among clinical and serological variables. The overall survival (OS) was assessed according to liver fibrosis and multivariate Cox regression analysis was used to identify independent predictors. In 13 out of 37 patients (35%) with IPF, a certain degree of liver fibrosis was documented. No correlation was found between liver stiffness and clinical-functional parameters. OS was lower in patients 'with liver fibrosis' than in patients 'without liver fibrosis' (median months 33 [23-55] vs. 63 [26-94], p = 0.038). Patients 'with liver fibrosis' presented a higher risk of death at seven years as compared to patients 'without liver fibrosis' (HR = 2.6, 95% CI [1.003-6.7], p = 0.049). Higher level of AST to platelet ratio index (APRI) was an independent predictor of survival (HR = 4.52 95% CI [1.3-15.6], p = 0.02). In our cohort, more than one-third of IPF patients had concomitant subclinical liver fibrosis that negatively affected OS. These preliminary claims further investigation aimed at clarifying the mechanisms beyond multiorgan fibrosis and its clinical implication in patients with IPF.
Identifiants
pubmed: 32451930
doi: 10.1007/s11739-020-02376-2
pii: 10.1007/s11739-020-02376-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
349-357Références
Sgalla G, Cocconcelli E, Tonelli R, Richeldi L (2016) Novel drug targets for idiopathic pulmonary fibrosis. Expert Rev Respir Med 10(4):393–405. https://doi.org/10.1586/17476348.2016.1152186 Epub 2016 Feb 26
doi: 10.1586/17476348.2016.1152186
pubmed: 26854382
Wenzke KE, Cantemir-Stone C, Zhang J, Marsh CB, Huang, K. Identifying common genes and networks in multi-organ fibrosis. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2012, pp 106–115
Jun JI, Lau LF (2018) Resolution of organ fibrosis. J Clin Invest 128(1):97–107
doi: 10.1172/JCI93563
Zeisberg M, Kalluri R (2013) Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 304(3):C216–C225. https://doi.org/10.1152/ajpcell.00328.2012
doi: 10.1152/ajpcell.00328.2012
pubmed: 23255577
Selman M, King J, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134(2):136–151
doi: 10.7326/0003-4819-134-2-200101160-00015
Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. NEJM 29(5):283–291
Raghu G, Collard HR, Egan JJ et al (2011) An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824
doi: 10.1164/rccm.2009-040GL
Raghu G, Remy-Jardin M, Myers JL et al (2018) American Thoracic Society diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 198(5):e44–e68
doi: 10.1164/rccm.201807-1255ST
Ley B, Ryerson CJ, Vittinghoff E et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684–691
doi: 10.7326/0003-4819-156-10-201205150-00004
Galiè N, Humbert M, Vachiery J-L et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 46:903–975
doi: 10.1183/13993003.01032-2015
Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48(5):835–847
doi: 10.1016/j.jhep.2008.02.008
Platon ML, Stefanescu H, Feier D, Maniu A, Badea R (2013) Performance of unidimensional transient elastography in staging chronic hepatitis C. Results from a cohort of 1,202 biopsied patients from one single center. J Gastrointest Liver Dis 22(2):157–166
Lieber CS, Weiss DG, Morgan TR, Paronetto F (2006) Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 101(7):1500–1508
doi: 10.1111/j.1572-0241.2006.00610.x
Lin ZH, Xin YN, Dong QJ et al (2011) Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53(3):726–736
doi: 10.1002/hep.24105
Wynn TA, Ramalingam TR (2013) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028–1040
doi: 10.1038/nm.2807
Friedman SL (2003) Liver fibrosis: from bench to bedside. J Hepatol 38(Suppl 1):S38–53
doi: 10.1016/S0168-8278(02)00429-4
Schuppan D, Ruehl M, Somasundaram R, Hahn EG (2001) Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21(3):351–372
doi: 10.1055/s-2001-17556
Schölmerich J, Holstege A (1990) Aetiology and pathophysiology of chronic liver disorders. Drugs 40(3):3–22
doi: 10.2165/00003495-199000403-00003
Perepelyuk M, Terajima M, Wang AY et al (2013) Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol 304(6):605–615
doi: 10.1152/ajpgi.00222.2012
Armanios MY, Chen JJL, Cogan JD et al (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356(13):1317–1326
doi: 10.1056/NEJMoa066157
Armanios M (2009) Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 10(1):45–61
doi: 10.1146/annurev-genom-082908-150046
Alder JK, Cogan JD, Brown AF et al (2011) Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLoS Genet 7(3):1–9
doi: 10.1371/journal.pgen.1001352
Diaz de Leon A, Cronkhite JT, Katzenstein ALA et al (2010) Telomere lengths, pulmonary fibrosis and telomerase (TERT) Mutations. PLoS One 5(5):e10680
doi: 10.1371/journal.pone.0010680
Sandrin L, Fourquet B, Hasquenoph J-M et al (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29(12):1705–1713
doi: 10.1016/j.ultrasmedbio.2003.07.001
Colletta C, Smirne C, Fabris C et al (2005) Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 42(4):838–845
doi: 10.1002/hep.20814
Foucher J, Chanteloup E, Vergniol J et al (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55(3):403–408
doi: 10.1136/gut.2005.069153
Kettaneh A, Marcellin P, Douvin C et al (2007) Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 46(4):628–634
doi: 10.1016/j.jhep.2006.11.010
Shaheen AAM, Wan AF, Myers RP (2007) FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 102(11):2589–2600
doi: 10.1111/j.1572-0241.2007.01466.x
Wai C-T, Greenson JK, Fontana RJ et al (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38(2):518–526
doi: 10.1053/jhep.2003.50346
Castéra L, Vergniol J, Foucher J et al (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128(2):343–350
doi: 10.1053/j.gastro.2004.11.018
Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M (2008) Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 48(4):606–613
doi: 10.1016/j.jhep.2007.11.020
Torrisi SE, Ley B, Kreuter M et al (2019) The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J. 53(3):1801587 Published 2019 Mar 7
doi: 10.1183/13993003.01587-2018